Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Search results for:

retifanlimab

retifanlimab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Zynyz INJECTION, INTRAVENOUS 25 mg/mL      
Comments:

Restricted to oncologist use in the outpatient setting for anal squamous cell carcinoma and Merkel Cell Carcinoma. If there is another preferred regimen, attempt prior to the use of retifanlimab. May be used as PAP.

 

 

 

 

 

Reviewed: February 2026              

Retifanlimab (ZYNYZ) Spotlight.pdf

Last updated: Mar. 13, 2026






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved